Endoscopic submucosal dissection for locally recurrent gastric neoplasia following endoscopic resection: a systematic review and meta-analysis.

Gastrointest EndoscMar 26, 2026 (epub)
Clinical ResearchGastroenterology

Tareq Alsaleh, Hamza Akram, Syed Hasaan Rahman et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and random-effects meta-analysis assessed salvage endoscopic submucosal dissection (ESD) for locally recurrent gastric neoplasia at or near a prior endoscopic resection scar, where fibrosis can make treatment technically challenging. Seven studies included 259 patients and 265 ESD procedures. Across five studies, pooled curative resection was 69.7% (95% CI, 60.6-78.1), and 8.2% (95% CI, 3.3-14.6) required surgery. En bloc and R0 resection rates were high, while local recurrence and reported adverse events were relatively low.

Key findings

  • Pooled curative resection was 69.7% (95% CI, 60.6-78.1; I 2 = 38%) across 5 studies and 243 ESDs.
  • Surgery was required in 8.2% (95% CI, 3.3-14.6; I 2 = 38.4%).
  • Pooled en bloc and R0 resection rates were 92.3% (95% CI, 79.1-99.7) and 87.5% (95% CI, 82.1-92.2), respectively.
  • Over a mean follow-up of 42 months, local recurrence was 2.0% (95% CI, 0.0-9.7); delayed bleeding and perforation were each 4.1%.

Why it matters

Recurrent lesions at a previous resection scar can be difficult to treat because of submucosal fibrosis. These pooled results suggest salvage ESD can achieve organ-preserving resection in many cases, with relatively low reported recurrence and morbidity. The findings help frame its potential role while underscoring that curative resection is not assured and some patients require surgery.

What to keep in mind

The evidence comprised seven studies, and estimates showed substantial heterogeneity for some outcomes, including en bloc resection and local recurrence.

Source

Published in Gastrointest Endosc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.